Thomas G. Martin

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Jesús G. Berdeja, Deepu Madduri, Saad Z. Usmani et al. · The Lancet · 2021 · 1.7K citations

Medicine, Hematology, Oncology +17

Teclistamab in Relapsed or Refractory Multiple Myeloma

Philippe Moreau, Alfred L. Garfall, Niels W.C.J. van de Donk et al. · New England Journal of Medicine · 2022 · 1.1K citations · Full text

Medicine, Hematology, Immunology +17

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

David S. Siegel, Thomas G. Martin, Michael Wang et al. · Blood · 2012 · 655 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

Thomas G. Martin, Saad Z. Usmani, Jesús G. Berdeja et al. · Journal of Clinical Oncology · 2022 · 633 citations · Full text

Medicine, Hematology, Immunology +17

A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma

Thomas G. Martin, Rachid Baz, Don M. Benson et al. · Blood · 2017 · 166 citations · Full text

Medicine, Hematology, Pharmacotherapy +13